Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Medtech Insight

Generics Bulletin

Samsung Bioepis Partners With Yuhan On Korean Adalimumab

Marketing Partnership Agreed For Adalloce Biosimilar Rival To Humira

Mar 16 2021

• By David Wallace

Korea Map Pin — Samsung Bioepis has extended its Korean partnership with Yuhan • Source: Shutterstock

Related Content

Samsung Bioepis Pushes Stelara Rival Into Phase I

Mar 01 2021

Four adalimumabs compete in EU

Oct 26 2018

Yuhan Replaces Merck To Market Samsung’s Biosimilars In Korea

Oct 12 2017

Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait

Nov 18 2019

Related Companies

Samsung Bioepis Co., Ltd.

Yuhan Corporation

Additional Topics

South Korea Asia Pacific Deals Biosimilars BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and Conditions Opens in new window

Privacy PolicyOpens in new window